Boehringer's Giotrif to get survival benefit on EU label; BMS sells Ixempra rights; No CV trial necessary for Esperion cholesterol med;

> European regulators recommended a label update for Boehringer Ingelheim's lung cancer drug Giotrif to cite a one-year overall survival benefit in a study in patients with a certain EGFR mutation, compared with chemotherapy. Release

> R-Pharma US bought the rights to Bristol-Myers Squibb's ($BMY) breast cancer treatment Ixempra and launched U.S. commercial operations to handle the drug. Report

> The FDA decided not to require a cardiovascular outcomes trial on Esperion Therapeutics' anti-cholesterol drug ETC-1002, a drug that could eventually compete with the forthcoming PCSK9 drugs. Report

> Kantar Health teamed up with Data2Life to flag early signals on drug side effects, based on data gleaned from a variety of real-world sources. Release

> Concordia Pharmaceuticals and Par Pharmaceutical settled charges of anti-competitive behavior leveled by the Federal Trade Commission, over an agreement not to compete sell rival generic versions of the ADHD drug Kapvay. Report

> Merck & Co. recalled 276,000 bottles of its chemotherapy drug branded and generic Temodar over cracks in child-proof caps. Report

A naloxone-dispensing clinic in Northern Kentucky helped change people's minds in favor of providing the opioid-overdose drug. Report

And Finally... Anthem issued a reminder to Medicare patients to switch to 90-day prescriptions in a move to boost adherence. Report

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The U.S. aesthetics business is booming with fillers and fat freezers garnering interest, and spurring marketing campaigns, post-lockdown COVID-19.